retatrutide efficacy weight loss and Safety of GLP‐1 Receptor Agonists, Dual Agonists, and for in Adults With Overweight or Obesity: A Bayesian NMA - Sinha - 2025 - Obesity Retatrutide—A Game Changer in Obesity

Exenatide was the worlds first clinically used GLP-1RA, developed in 1995 and approved for the treatment of type 2 diabetes mellitus (T2DM) in 2005 due to its proven ability to regulate postprandial glucose levels effectively (DeFronzo et al., 2005

Complete Batch Testing Each product includes a Certificate of Analysis (COA) with verifiable data from independent laboratories

Retatrutide is not FDA-approved and is currently available only through clinical trials

It took Bernard several attempts to isolate the glycogen molecule

Monitoring cardiovascular effects Given the potential cardiovascular effects of retatrutide, close monitoring of heart rate and rhythm is recommended during treatment

Federal law prohibits Medicare from covering weight loss medications